Choose One: Do Not Use Both Together
You should pick one medication, not use both together. Both Spiriva HandiHaler (tiotropium) and Anoro Ellipta (umeclidinium/vilanterol) contain long-acting muscarinic antagonists (LAMAs), and combining two anticholinergic medications significantly increases the risk of anticholinergic adverse effects without proven clinical benefit.
Why Not Both?
Drug Label Warnings Against Dual Anticholinergics
The FDA label for Spiriva explicitly states to "avoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs" due to additive anticholinergic interactions 1. Anoro Ellipta contains umeclidinium, which is itself a LAMA (anticholinergic) 2. Using both means you're doubling up on the same drug class.
Safety Concerns with Dual Anticholinergics
Research demonstrates that combining short- and long-acting anticholinergics significantly increases the risk of acute urinary retention (OR 1.84; 95% CI 1.25-2.71), with men and those with benign prostatic hypertrophy at highest risk 3. While this study examined ipratropium plus tiotropium, the principle applies to any dual anticholinergic therapy. The clinical significance of any spirometric improvements does not justify the increased anticholinergic adverse effects 3.
Which One Should You Choose?
If Currently on Spiriva and Symptomatic: Switch to Anoro Ellipta
Anoro Ellipta (LAMA/LABA combination) is superior to tiotropium monotherapy for patients with persistent symptoms 4. The evidence strongly supports this:
- Lung function improvements: Anoro provides 52-90 mL greater trough FEV₁ improvement compared to tiotropium alone 5, 6
- Symptom control: 63% of patients achieved clinically meaningful dyspnea improvements (TDI ≥1 unit) with Anoro versus 49% with tiotropium (OR 1.78; p≤0.01) 5
- Reduced rescue medication use: 0.1 fewer puffs/day with statistical significance 5
- Mortality benefit: The 2023 Canadian Thoracic Society guidelines emphasize that dual LAMA/LABA therapy reduces mortality in moderate-severe COPD 7
GOLD Guidelines Support LAMA/LABA Combinations
For patients with persistent breathlessness on monotherapy, GOLD 2017 explicitly recommends using two bronchodilators (LAMA/LABA combination) 4. The guidelines state that LAMA/LABA combinations showed superior results in patient-reported outcomes compared to single bronchodilators and were superior to LABA/ICS combinations in preventing exacerbations 4.
Clinical Algorithm
Step 1: Assess current symptom control on Spiriva
- If well-controlled with minimal symptoms → Continue Spiriva alone
- If persistent dyspnea (mMRC ≥2) or frequent rescue medication use → Switch to Anoro
Step 2: If switching to Anoro
- Stop Spiriva completely when starting Anoro (do not overlap)
- Anoro provides both LAMA (umeclidinium) and LABA (vilanterol) in one inhaler
- Monitor for anticholinergic side effects: dry mouth, urinary retention, narrow-angle glaucoma symptoms
Step 3: If still symptomatic on Anoro after 4-12 weeks
- Consider adding inhaled corticosteroid (triple therapy) if:
- History of ≥2 exacerbations per year
- Blood eosinophils ≥300 cells/μL 8
- Do NOT add Spiriva back
Common Pitfalls to Avoid
Never overlap anticholinergics: Patients sometimes continue Spiriva "just in case" when starting Anoro—this is dangerous and contraindicated 1
Watch for urinary retention: Particularly in older men with prostatic symptoms—counsel patients to report difficulty urinating immediately 3
Device technique matters: Spiriva uses HandiHaler (capsule-based), Anoro uses Ellipta (strip-based). Ensure proper training on whichever device is chosen
Cost considerations: While Anoro is more expensive, the superior efficacy and mortality benefit justify the cost in symptomatic patients 7, 5
The evidence unequivocally supports choosing one medication over combining both, with Anoro Ellipta being the preferred choice for patients with persistent symptoms on tiotropium monotherapy.